Firsekibart as a Prophylactic Treatment for Acute Gout Flare in Participants Initiating Urate‐Lowering Therapy: A Phase 2, Randomized, Open‐Label, Multicenter, Active‐Controlled Trial

医学 痛风 耐受性 预防性治疗 内科学 秋水仙碱 外科 临床试验 不利影响 火炬 背景(考古学) 随机对照试验
作者
Yiyun Yu,Yu Xue,Jiankang Hu,Ning Zhang,Rongbin Li,Hongtao Guo,Long Qian,Wei Gou,H. J. Yang,Li Mao,Jing Yu,Shengyun Liu,Qian Xu,Tianhong Luo,Hejian Zou
出处
期刊:ACR open rheumatology [Wiley]
卷期号:7 (11): e70111-e70111 被引量:4
标识
DOI:10.1002/acr2.70111
摘要

OBJECTIVE: To evaluate the efficacy and safety of firsekibart versus colchicine for prophylaxis against acute gout flares in participants initiating urate-lowering therapy (ULT). METHODS: In this randomized, multicenter, open-label, active-controlled, phase 2 trial, participants were randomized (1:1:1) to receive a single subcutaneous injection of firsekibart 100 mg or 200 mg or oral colchicine 0.5 mg/day for 12 weeks. ULT was initiated at baseline or within 1 week before screening. The primary endpoint was the mean number of acute gout flares per participant over 12 weeks. RESULTS: A total of 162 participants received firsekibart 100 mg (n = 55), 200 mg (n = 52), or colchicine (n = 55). Baseline characteristics were comparable between groups. No flares were observed in the firsekibart 200 mg group within 12 weeks. The adjusted mean number of acute gout flares per participant was 0.02 with firsekibart 100 mg and 0.34 with colchicine, with a rate ratio of 0.05 (95% confidence interval 0.01-0.43; P = 0.0060). Both treatment groups receiving firsekibart (at either dose) had a lower proportion of patients with at least one acute gout flare than the colchicine group. Firsekibart had a favorable safety profile, with no treatment-emergent adverse events (AEs) leading to treatment discontinuation/study withdrawal, no treatment-related serious AEs, and no deaths. CONCLUSION: Firsekibart provided superior prophylaxis against acute gout flares compared with colchicine in patients initiating ULT, with a favorable tolerability profile, supporting its potential as a treatment option for patients with gout initiating ULT.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李元完成签到,获得积分10
刚刚
刚刚
刚刚
刚刚
刚刚
刚刚
刚刚
风清扬发布了新的文献求助10
1秒前
1秒前
特仑苏发布了新的文献求助10
1秒前
1秒前
2秒前
2秒前
3秒前
3秒前
在水一方的应助被昔年采纳,获得10
3秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
斯多姆发布了新的文献求助10
5秒前
5秒前
黑米粥发布了新的文献求助200
5秒前
6秒前
opp完成签到,获得积分10
6秒前
6秒前
CWJ发布了新的文献求助20
7秒前
8秒前
8秒前
8秒前
8秒前
elysia发布了新的文献求助10
8秒前
gbh的应助被123采纳,获得10
8秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183880
求助须知:如何正确求助?哪些是违规求助? 9573054
关于积分的说明 21828982
捐赠科研通 7780959
什么是DOI,文献DOI怎么找? 3434134
关于科研通互助平台的介绍 2558315
邀请新用户注册赠送积分活动 2480634